Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Kelly

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Pharmaceuticals (Basel, Switzerland)|December 30, 2014
Clinical use of proteasome inhibitors in the treatment of multiple myelomaNoah M Merin, Kevin R Kelly
Targeted Oncology|May 7, 2011
Mechanisms of mTOR inhibitor resistance in cancer therapyJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Cancer Management and Research|October 24, 2012
Autophagy as a target for cancer therapy: new developmentsJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Expert Review of Hematology|November 19, 2010
Clinical activity of laromustine (Onrigin™) in hematologic malignanciesYesid Alvarado, Ronan Swords, Kevin R Kelly, et al.
Expert Opinion on Investigational Drugs|July 18, 2012
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapySteffan T Nawrocki, Patrick Griffin, Kevin R Kelly, et al.
Cancers|June 16, 2018
Oncolytic Viruses for Multiple Myeloma TherapyChristine M Calton, Kevin R Kelly, Faiz Anwer, et al.
Targeted Oncology|April 19, 2011
Mammalian target of rapamycin as a target in hematological malignanciesKevin R Kelly, Julie H Rowe, Swaminathan Padmanabhan, et al.
Patterns (New York, N.Y.)|May 27, 2024
DeepDecon accurately estimates cancer cell fractions in bulk RNA-seq dataJiawei Huang, Yuxuan Du, Andres Stucky, et al.
Plos Computational Biology|June 4, 2025
DeepDeconUQ estimates malignant cell fraction prediction intervals in bulk RNA-seq tissueJiawei Huang, Yuxuan Du, Kevin R Kelly, et al.
Expert Opinion on Emerging Drugs|May 27, 2009
Emerging drugs in the treatment of pancreatic cancerDevalingam Mahalingam, Kevin R Kelly, Ronan T Swords, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Pharmaceuticals (Basel, Switzerland)|December 30, 2014
Clinical use of proteasome inhibitors in the treatment of multiple myelomaNoah M Merin, Kevin R Kelly
Targeted Oncology|May 7, 2011
Mechanisms of mTOR inhibitor resistance in cancer therapyJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Cancer Management and Research|October 24, 2012
Autophagy as a target for cancer therapy: new developmentsJennifer S Carew, Kevin R Kelly, Steffan T Nawrocki
Expert Review of Hematology|November 19, 2010
Clinical activity of laromustine (Onrigin™) in hematologic malignanciesYesid Alvarado, Ronan Swords, Kevin R Kelly, et al.
Expert Opinion on Investigational Drugs|July 18, 2012
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapySteffan T Nawrocki, Patrick Griffin, Kevin R Kelly, et al.
Cancers|June 16, 2018
Oncolytic Viruses for Multiple Myeloma TherapyChristine M Calton, Kevin R Kelly, Faiz Anwer, et al.
Targeted Oncology|April 19, 2011
Mammalian target of rapamycin as a target in hematological malignanciesKevin R Kelly, Julie H Rowe, Swaminathan Padmanabhan, et al.
Patterns (New York, N.Y.)|May 27, 2024
DeepDecon accurately estimates cancer cell fractions in bulk RNA-seq dataJiawei Huang, Yuxuan Du, Andres Stucky, et al.
Plos Computational Biology|June 4, 2025
DeepDeconUQ estimates malignant cell fraction prediction intervals in bulk RNA-seq tissueJiawei Huang, Yuxuan Du, Kevin R Kelly, et al.
Expert Opinion on Emerging Drugs|May 27, 2009
Emerging drugs in the treatment of pancreatic cancerDevalingam Mahalingam, Kevin R Kelly, Ronan T Swords, et al.
Pageof 5